Sleep Apnea Diagnostic System Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2024-2030

Report Code: HCR 80227 Report Format: PDF + Excel

Sleep Apnea Diagnostic Devices Market Overview:

Sleep Apnea Diagnostic Devices size is estimated to reach US$5.3 billion by 2030, growing at a CAGR of 7.9% during the forecast period 2024-2030. Large pool of undiagnosed sleep apnea patients and technological innovation in devices for sleep apnea are expected to propel the growth of Sleep Apnea Diagnostic Devices.

Additionally, the increasing adoption of home sleep apnea testing (HSAT) devices allow individuals to undergo sleep apnea testing in the comfort of their own homes, rather than in a sleep laboratory. HSAT devices typically include a small wearable monitor that records key physiological parameters during sleep, such as airflow, oxygen levels, and respiratory effort. The convenience and cost-effectiveness of HSAT devices have led to their growing popularity, particularly among patients with suspected sleep apnea and those seeking alternatives to traditional in-lab polysomnography (PSG) tests. The integration of artificial intelligence (AI) and machine learning (ML) technologies into sleep apnea diagnostic and therapeutic devices are being utilized to analyze sleep data collected by wearable devices, CPAP machines, and other sleep apnea devices, enabling personalized treatment recommendations and predictive analytics. For instance, AI-powered CPAP machines can automatically adjust pressure settings based on real-time feedback from the patient's sleep patterns, optimizing therapy efficacy and patient comfort. Additionally, AI-driven sleep apnea screening tools can help identify high-risk individuals and facilitate early diagnosis and intervention, leading to better patient outcomes.

Market Snapshot: 


Sleep Apnea Diagnostic Devices - Report Coverage:

The “Sleep Apnea Diagnostic Devices Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Sleep Apnea Diagnostic Devices.
           Attribute                               Segment

By Type

● Polysomnography Devices

  • Clinical PSG Devices

  • Ambulatory PSG Devices

● Home Sleep Testing Devices

● Oximeters

  • Fingertip Oximeters

  • Hand-held Oximeters

  • Wrist-worn Oximeters

  • Tabletop Oximeters

● Actigraphy System

● Sleep Screening Devices

By End-User

  • Sleep Laboratories & Hospitals

  • Home Care Settings/Individual

By Geography

  • North America (U.S., Canada and Mexico)

  • Europe (Germany, France, UK, Italy, Spain, Netherlands and Rest of Europe),

  • Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific),

  • South America (Brazil, Argentina, Chile, Colombia and Rest of South America)

  • Rest of the World (Middle East and Africa).

COVID-19 / Ukraine Crisis - Impact Analysis:  

● The COVID-19 pandemic significantly impacted the Sleep Apnea Diagnostic Devices, both positively and negatively. Initially, the market experienced disruptions in the supply chain due to lockdown measures, leading to manufacturing delays and shortages of essential components for devices like CPAP machines. Moreover, patients postponed non-urgent medical appointments, affecting the diagnosis and treatment of sleep apnea, thereby reducing the demand for devices temporarily.

● In Ukraine, the impact of the conflict and economic instability on the Sleep Apnea Diagnostic Devices has been profound. The ongoing crisis has strained the healthcare system, resulting in limited access to medical facilities and supplies. This has likely hindered the diagnosis and treatment of sleep apnea, leading to reduced demand for devices. Additionally, economic hardships faced by individuals may have made it challenging to afford expensive devices like CPAP machines or oral appliances.

Key Takeaways:

● Rising Prevalence of Sleep Apnea

The increasing prevalence of sleep apnea is a significant driver of the sleep apnea diagnostic devices market. Factors such as obesity, aging populations, and lifestyle changes contribute to the rising incidence of sleep apnea. As awareness of the condition grows, more individuals seek diagnosis and treatment. This heightened demand for accurate and effective diagnostic tools, such as polysomnography devices, home sleep apnea tests, and pulse oximeters, is driving market growth. Early and accurate diagnosis is crucial for managing sleep apnea and reducing associated health risks, further boosting the need for advanced diagnostic devices. 

● Sleep Laboratories is the fastest growing segment

In the Sleep Apnea Diagnostic Devices forecast, Sleep Laboratories segment is estimated to grow with a CAGR of 6.3% during the forecast period. There is an increasing awareness and recognition of sleep disorders, including sleep apnea, among the general population and healthcare professionals. This heightened awareness has led to a growing demand for sleep studies and diagnostic services provided by sleep laboratories. As more individuals seek diagnosis and treatment for sleep-related issues, the need for comprehensive sleep testing facilities becomes paramount. Advancements in technology have significantly improved the efficiency and accuracy of sleep studies conducted in laboratories. State-of-the-art equipment, such as polysomnography (PSG) systems and portable home sleep testing devices, allow for detailed monitoring and analysis of sleep patterns and respiratory parameters. These technological innovations not only enhance the diagnostic capabilities of sleep laboratories but also contribute to greater patient comfort and convenience, leading to increased utilization of these services. The rising prevalence of risk factors associated with sleep disorders, such as obesity, cardiovascular disease, and diabetes, has fueled the demand for sleep apnea diagnosis and management. Healthcare providers increasingly recognize the importance of identifying and addressing sleep-related issues as part of comprehensive patient care, further driving the growth of sleep laboratories. 

● North America to Hold Largest Market Share

According to the Sleep Apnea Diagnostic Devices analysis, North America region is estimated to hold the largest market share of 43% in 2023. The region has a high prevalence of sleep apnea, attributed to lifestyle factors, such as obesity and sedentary habits, as well as an aging population prone to respiratory disorders. Consequently, there is a significant patient pool in North America requiring diagnosis and treatment for sleep apnea, driving the demand for sleep apnea devices. Moreover, the region boasts advanced healthcare infrastructure and a robust reimbursement framework, facilitating access to diagnostic tests and therapeutic interventions for sleep disorders. Additionally, the presence of key market players, including ResMed Inc., Philips Respironics, and Fisher & Paykel Healthcare, who continually innovate and introduce advanced sleep apnea devices, contributes to the dominance of North America in this market. Furthermore, increasing awareness campaigns and initiatives by healthcare organizations and government bodies regarding the importance of sleep health and the treatment of sleep disorders further bolster market growth in the region. In November 2023, US FDA clears Vivos Therapeutics' oral device for sleep apnea. Overall, North America's favorable healthcare landscape, coupled with a large patient population and innovative product offerings, solidify its position as the leading market for sleep apnea devices.

● Large Pool of Undiagnosed Sleep Apnea Patients

lack of awareness among the general population about sleep apnea and its symptoms contributes significantly to underdiagnosis. Many individuals may not recognize the signs of sleep apnea, such as snoring, daytime fatigue, and witnessed pauses in breathing during sleep, leading them to overlook seeking medical attention for their symptoms. Growing awareness about sleep apnea and its health implications is driving higher diagnosis rates, fueling the demand for diagnostic devices. Public health campaigns, educational initiatives, and increased media coverage have raised awareness about the symptoms and risks of untreated sleep apnea, such as cardiovascular disease, stroke, and diabetes. As more individuals recognize the importance of diagnosis and treatment, the demand for sleep apnea diagnostic devices rises, contributing to market growth.

● Technological Innovation in Devices for Sleep Apnea

Technological innovation is a key driver of advancements in devices for sleep apnea, enhancing both diagnosis and treatment. The miniaturization of components, leading to more compact and portable devices that improve patient comfort and compliance. For instance, CPAP machines have become smaller and quieter, making them less obtrusive during sleep. Additionally, advancements in sensor technology have enabled the development of smart devices capable of monitoring sleep patterns and adjusting therapy settings in real-time based on patient needs. Integration with smartphone apps and cloud-based platforms allows for remote monitoring and data analysis, facilitating better patient management and healthcare provider oversight. Moreover, the emergence of wearable devices and home sleep testing kits empowers individuals to monitor their sleep health conveniently and affordably, increasing accessibility to diagnosis and treatment. Furthermore, the incorporation of artificial intelligence algorithms enables predictive analytics and personalized therapy recommendations, optimizing treatment outcomes. Overall, ongoing technological innovation continues to drive improvements in sleep apnea devices, leading to enhanced effectiveness, comfort, and patient outcomes.

● High Cost of Diagnosis & Treatment for Sleeping Disorder Challenges the Market Growth

One of the major challenges in the sleep apnea diagnostic devices market is the high cost of these devices. Advanced diagnostic tools, such as polysomnography systems and sophisticated home sleep apnea tests, can be expensive, making them less accessible to a broad segment of the population. The high cost can deter patients, especially those without adequate insurance coverage, from undergoing necessary diagnostic procedures. Additionally, healthcare providers, particularly in low-resource settings, may face financial constraints in acquiring and maintaining these devices, limiting their ability to offer comprehensive sleep apnea diagnostic services. Additionally, the indirect costs related to lost productivity and healthcare utilization further compound the economic burden of sleep disorders on individuals and society. Treatment options such as continuous positive airway pressure (CPAP) machines or oral appliances for conditions like sleep apnea can also be costly, making them inaccessible to some patients. These financial barriers hinder timely diagnosis and treatment, leading to undiagnosed or untreated cases and ultimately impeding market growth. Moreover, sleeping disorder encompasses a wide spectrum of diseases with significant individual health consequences and high economic cost to society. Addressing these cost challenges through initiatives aimed at increasing affordability and accessibility of diagnostic tools and treatment options is crucial for overcoming this constraint and fostering market expansion.
                                                         For More Details on This Report - Request for Sample

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Sleep Apnea Diagnostic Devices. The top 10 companies in this industry are listed below:
  1. BMC Medical Co
  2. ResMed Inc.
  3. Braebon Medical Corporation
  4. Compumedics Limited 
  5. Drive DeVilbiss International
  6. Fisher & Paykel Healthcare Limited.
  7. Koninklijke Philips N.V.
  8. Löwenstein Medical Technology GmbH + Co. KG.
  9. SomnoMed
  10. Nihon Kohden Corporation

Scope of Report: 

        Report Metric                                 Details

Base Year Considered


Forecast Period




Market Size in 2030

$5.3 billion

Segments Covered

Type, End-User

Geographies Covered

North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Netherlands and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Colombia and Rest of South America), Rest of the World (Middle East and Africa).

Key Market Players

  1. BMC Medical Co

  2. ResMed Inc.

  3. Braebon Medical Corporation

  4. Compumedics Limited

  5. Drive DeVilbiss International

  6. Fisher & Paykel Healthcare Limited.

  7. Koninklijke Philips N.V.

  8. Löwenstein Medical Technology GmbH + Co. KG.

  9. SomnoMed

  10. Nihon Kohden Corporation

For more Lifesciences and Healthcare Market reports, please click here
1. Sleep Apnea Diagnostic Devices - Overview
    1.1. Definitions and Scope
2. Sleep Apnea Diagnostic Devices - Executive Summary
3. Sleep Apnea Diagnostic Devices - Comparative Analysis
    3.1. Company Benchmarking - Key Companies
    3.2. Global Financial Analysis - Key Companies
    3.3. Market Share Analysis - Key Companies
    3.4. Patent Analysis
    3.5. Pricing Analysis
4. Sleep Apnea Diagnostic Devices - Start-up Companies Scenario (Premium)
    4.1. Key Start-up Company Analysis by
        4.1.1. Investment
        4.1.2. Revenue
        4.1.3. Venture Capital and Funding Scenario
5. Sleep Apnea Diagnostic Devices – Market Entry Scenario Premium (Premium)
    5.1. Regulatory Framework Overview
    5.2. New Business and Ease of Doing Business Index
    5.3. Case Studies of Successful Ventures
6. Sleep Apnea Diagnostic Devices - Forces
    6.1. Market Drivers
    6.2. Market Constraints
    6.3. Market Challenges
    6.4. Porter's Five Force Model
        6.4.1. Bargaining Power of Suppliers
        6.4.2. Bargaining Powers of Customers
        6.4.3. Threat of New Entrants
        6.4.4. Rivalry Among Existing Players
        6.4.5. Threat of Substitutes
7. Sleep Apnea Diagnostic Devices – Strategic Analysis
    7.1. Value Chain Analysis
    7.2. Opportunities Analysis
    7.3. Market Life Cycle
8. Sleep Apnea Diagnostic Devices – By Type (Market Size – $Million/$Billion) 
    8.1. Polysomnography Devices 
        8.1.1. Clinical PSG Devices
        8.1.2. Ambulatory PSG Devices
    8.2. Home Sleep Testing Devices
    8.3. Oximeters 
        8.3.1. Fingertip Oximeters
        8.3.2. Hand-held Oximeters
        8.3.3. Wrist-worn Oximeters
        8.3.4. Tabletop Oximeters
    8.4. Actigraphy System
    8.5. Sleep Screening Devices
9. Sleep Apnea Diagnostic Devices – By End-User (Market Size – $Million/$Billion) 
    9.1. Sleep Laboratories & Hospitals
    9.2. Home Care Settings/Individual
10. Sleep Apnea Diagnostic Devices – By Geography (Market Size – $Million/$Billion) 
    10.1. North America
        10.1.1. Canada
        10.1.2. Mexico
        10.1.3. U.S.
    10.2. South America
        10.2.1. Argentina
        10.2.2. Brazil
        10.2.3. Chile
        10.2.4. Colombia
        10.2.5. Rest of South America
    10.3. Europe
        10.3.1. France
        10.3.2. Germany
        10.3.3. Italy
        10.3.4. Netherlands
        10.3.5. Belgium
        10.3.6. Spain
        10.3.7. UK
        10.3.8. Denmark
        10.3.9. Rest of Europe
    10.4. APAC
        10.4.1. China
        10.4.2. Japan
        10.4.3. India
        10.4.4. South Korea
        10.4.5. Australia and New Zealand
        10.4.6. Indonesia
        10.4.7. Taiwan
        10.4.8. Malaysia
        10.4.9. Rest of APAC
    10.5. RoW
        10.5.1. Saudi Arabia
        10.5.2. South Africa
   Rest of Africa
11. Sleep Apnea Diagnostic Devices – Entropy
12. Sleep Apnea Diagnostic Devices – Industry/Segment Competition Landscape (Premium)
    12.1. Market Share Analysis
        12.1.1. Market Share by Region – Key Companies
        12.1.2. Market Share by Country – Key Companies
    12.2. Competition Matrix
    12.3. Best Practices for Companies
13. Sleep Apnea Diagnostic Devices – Key Company List by Country Premium (Premium)
14. Sleep Apnea Diagnostic Devices - Company Analysis
    14.1. BMC Medical Co
    14.2. ResMed Inc.
    14.3. Braebon Medical Corporation
    14.4. Compumedics Limited 
    14.5. Drive DeVilbiss International
    14.6. Fisher & Paykel Healthcare Limited
    14.7. Koninklijke Philips N.V.
    14.8. Löwenstein Medical Technology GmbH + Co. KG.
    14.9. SomnoMed
    14.10. Nihon Kohden Corporation

"Financials to the Private Companies would be provided on best-effort basis."

Connect with our experts to get customized reports that best suit your requirements. Our 
reports include global-level data, niche markets and competitive landscape.

The Sleep Apnea Diagnostic Devices is projected to grow at a CAGR of 7.9% during the forecast period 2024-2030.

Global Sleep Apnea Diagnostic Devices size is estimated to be $2.9 billion in 2023 and is projected to reach $5.3 billion by 2030.

The leading players in the Sleep Apnea Diagnostic Devices are BMC Medical Co, ResMed Inc., Braebon Medical Corporation, Compumedics Limited, Drive DeVilbiss International, and Others.

Increasing adoption of home sleep testing and Integration of AI & ML are the major trends in Sleep Apnea Diagnostic Devices.

Large pool of undiagnosed sleep apnea patients and Technological innovation in devices for sleep apnea are expected to drive the growth of Sleep Apnea Diagnostic Devices. Emerging market expansion and technological advancements to create growth opportunities in the market.